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A B S T R A C T
The purpose of this study was to conduct an interlaboratory ring-study, with six partners (academic and in-
dustrial), investigating the measurement of intrinsic dissolution rate (IDR) using surface dissolution imaging
(SDI) equipment. Measurement of IDR is important in pharmaceutical research as it provides characterising
information on drugs and their formulations. This work allowed us to assess the SDI’s interlaboratory perfor-
mance for measuring IDR using a defined standard operating procedure (see supporting information) and six
drugs assigned as low (tadalafil, bromocriptine mesylate), medium (carvedilol, indomethacin) and high (ibu-
profen, valsartan) solubility compounds. Fasted State Simulated Intestinal Fluid (FaSSIF) and blank FaSSIF
(without sodium taurocholate and lecithin) (pH 6.5) were used as media. Using the standardised protocol an IDR
value was obtained for all compounds and the results show that the overall IDR rank order matched the solubility
rank order. Interlaboratory variability was also examined and it was observed that the variability for lower
solubility compounds was higher, coefficient of variation> 50%, than for intermediate and high solubility
compounds, with the exception of indomethacin in FaSSIF medium. Inter laboratory variability is a useful de-
scriptor for understanding the robustness of the protocol and the system variability. On comparison to another
published small-scale IDR study the rank ordering with respect to dissolution rate is identical except for the high
solubility compounds. This results indicates that the SDI robustly measures IDR however, no recommendation on
the use of one small scale method over the other is made.
1. Introduction
The most convenient and frequent way of administering drugs is via
the oral route [1]. Generally, dosage forms consist of an active phar-
maceutical ingredient (API) and excipients, which help to ensure the
drug reaches its site of action, prevent unwanted decomposition and in
some cases controlling release. To exert an effect the drug must: dis-
solve in the aqueous environment of the gastrointestinal tract; remain
in solution to be available for absorption; and be sufficiently lipophilic
to be absorbed. The key drug attributes, solubility and permeability, are
succinctly classified in the widely used Biopharmaceutics Classification
System (BCS) [2].
1.1. Solubility and dissolution
Drug solubility and dissolution are interrelated parameters im-
portant for bioavailability and can be affected by internal as well as
external factors. Internal factors include the drug’s chemical structure,
particle size and crystal form as well as any ionisable groups in the
molecule. The external factors include the gastrointestinal (GI) tract
environment and behaviour. The GI tract environment for example
contains bile salts, phospholipids, fatty acids and proteins in different
concentrations throughout the digestive tract and these have an impact
on drug behaviour. Solubilisers such as bile salts and lecithin for ex-
ample can increase solubility of lipophilic drugs [3,4]. In addition the
https://doi.org/10.1016/j.ejpb.2020.02.005
Received 1 May 2019; Received in revised form 20 January 2020; Accepted 11 February 2020
⁎ Corresponding author.
E-mail address: ibrahim.khadra@strath.ac.uk (I. Khadra).
European Journal of Pharmaceutics and Biopharmaceutics 150 (2020) 24–32
Available online 14 February 2020
0939-6411/ © 2020 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license 
(http://creativecommons.org/licenses/BY/4.0/).
T
GI tract luminal content viscosity, mixing, and flow pattern also vary
[5] and pH varies between the stomach (pH 1.5–4) and intestine (pH
5–7) [6]. Depending upon the drug’s pKa ionisation and solubility will
therefore vary and the use of salt forms may result in completely dif-
ferent drug solubilities and dissolution rates in GI tract fluids than in
pure water [3,7,8]. Biorelevant media such as FaSSIF (Fasted Stated
Simulated Intestinal Fluid) are commonly used to more accurately
mimic in vivo conditions, resulting in better predictions overall [9].
These media have frequently been used to mimic human intestinal
fluids for greater biorelevance in solubility and dissolution experiments
[3,10,11].
1.2. Intrinsic dissolution rate (IDR)
Dissolution is an important in vitro test, as it provides crucial in-
formation on the release of the API from a formulated product which
can then be used to guide formulation development, and ultimately,
provide assurance of reliable drug release in humans. The intrinsic
dissolution rate (IDR) is defined as the amount of drug dissolved per
unit time per unit area and is therefore expressed as a rate, in contrast
to the thermodynamic equilibrium reported by solubility data. IDR
determination can be used in the selection of optimal forms and ver-
sions (e.g. salts), and can improve prediction of drug behaviour in the
dynamic situation found in the GI tract [12]. In addition, studies carried
out using disc IDR were reported to be a simple, convenient and feasible
way to determine BCS solubility class [13]. Yu et al. showed that IDR
values determined using Wood’s apparatus can be used to classify
compounds as either high or low solubility under different pH condi-
tions. The classification matched the BCS system for solubility based on
an IDR cut-off of 0.1 mg/min/cm2 [13].
Apparatus for IDR is described by pharmacopoeias and includes the
rotating disk system (or Wood’s apparatus). This is a modified USP I/II
set up whereby a disc of API with a known surface area is rotated in a
dissolution vessel and the concentration at set time points measured.
IDR is expressed by the Nernst-Brunner adaptation of the Noyes
Whitney equation as [14]
= −dC
dt
DA
Vh
Cs Cb( )
(1)
where C is the concentration of API dissolved (mg/mL), t is the sam-
pling time (min), D is the diffusion coefficient (cm2/min), A is the
surface area (cm2), V is the volume of the medium (mL), h is the
boundary layer thickness at interface between drug solid and solution
(cm), Cs and Cb are the concentrations at saturation (present in the
boundary layer) and in the bulk solution respectively (mg/mL).
Diffusion coefficient of an API is affected by properties of the dis-
solution media, and in biorelevant media, the diffusion coefficient is a
function of both the diffusion of the unbound API and the diffusion of
the API within micelles [15,16].
= +D D f D feff mono mono agg agg (2)
where Deff is the effective diffusion coefficient, Dmono and Dagg is the
diffusion coefficient of the unbound (monomer) and micelle bound
(aggregate) API respectively (cm2/min), and f is the fraction of the
monomer and aggregated API.
The work here will focus on the IDR of compounds in two media
(FaSSIF and blank FaSSIF). IDR is related to dissolution rate equation
and is a function of area whereby:
= ∗ = −IDR dc
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1.3. Small scale intrinsic dissolution apparatus
The use of Wood’s apparatus to determine IDR is rarely feasible
during early development due to the amount of API required.
Miniaturised methods have therefore been developed which need only
minimal drug, and utilise small volume vials (rotating and stationary
disc systems), 96-well plates, flow through cells, and optical microscopy
[17–22]. An example of a system utilising small volume vials (up to
20 mL) is the Pion µDISS Profiler™, which can measure disc, powder
and controlled suspensions [23–25]. Standardised procedures for IDR
determination using the μDISS Profiler™ were proposed based on an
interlaboratory study [26] as part of the IMI OrBiTo collaboration
[27,28]. The ability of the μDISS Profiler™ to use minimal amounts of
API and the ease of use makes it an attractive option for IDR determi-
nation in early preformulation work. In this study, further inter-
laboratory comparisons were conducted to evaluate an alternative
small-scale IDR method, which combines IDR measurement with UV
imaging of the dissolution process.
The IDR measurement technique investigated in this study utilises
the Sirius Surface Dissolution Imaging (SDI) system [29] whuich allows
real-time monitoring of dissolution and release from the surface of a
small compressed disc of drug. Dissolution studies performed over
5–30 min at specific flow rates allows determinations of IDRs, surface
concentrations and the cumulative amount of drug dissolved using UV
imaging. Moreover, videos can be generated for visual examination of
the dissolution process [30–35]. Examples of IDR studies using UV
imaging include comparisons between different forms of drugs and
their salts/hydrates, and between micronised and nonmicronised ma-
terial. Form changes can also be studied with the use of simultaneous
Raman spectroscopy. The system has also been used to determine dif-
fusion coefficients and solubility [35–38].
The SDI works by filtering light through a bandpass filter, followed
by a diffuser to refocus on a specific UV wavelength. The light then
passes through a lens to collimate it and is presented to the front of a
quartz flow cell containing the sample. The detector readout is passed
to the computer [37,39,40], where the software analyses 3 zones from
the image (Fig. 1).
A published convection dissolution model, developed by Nelson and
Shah [41,42], which has been applied to both static and flow through
systems and accounts for changes in velocity and concentration gra-
dients above the surface has been applied to the SDI. For circular
compacts, the dissolution rate (R) is represented by:
̂= ±D c rR 2.157. . . I .2/3 0 1/3 5/3 (4)
where D is the diffusivity (cm2/min), c0 is the solubility (mg/mL), r is
the compact radius (cm), and α is the shear rate in boundary layer
=α Q
H W
6
2 (5)
where Q is the volumetric flow rate (mL), H is the height of channel
(cm), W is the width of channel (cm). Using the SDI data analysis
software the IDR is calculated from [43]:
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where z is the height above z-origin (cm – variable, set by analyst), vz is
the velocity at z, M is the molecular weight (Da), cz is the concentration
at z (μg/mL),W is the width of flow cell channel (cm), Δz is the effective
pixel height (cm), S is the surface area of sample (cm2), H is the height
of flow cell channel in observation region (cm), Q = volumetric flow
rate (mL/min).
The purpose of this work was to conduct an interlaboratory ring
study using the Sirius SDI apparatus to measure IDR. To this end the
variability of IDR values measured at different sites was assessed. An
investigation into molar extinction coefficient (MEC) values and
variability was also conducted. A standardised procedure for
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compressing the API powders into compacts was utilised and each
partner used a pre-defined protocol for each of the six APIs. The IDR
work was carried out over six partner sites (two academic and four
industrial) using the same batch for each of the compounds unless
specified. This will provide information on the robustness of the SDI
system for IDR measurement when sites use a standard method, pro-
viding a level of confidence in the data generated. A comparison be-
tween the μDISS Profiler™ system and SDI results and variability was
carried out to provide information on the usefulness of the flow through
imaged IDR data [26].
Andersson et al. described boundaries for high, intermediate and
low solubility APIs whereby disc and/or powder IDR determination can
be used [26]. The six compounds chosen for this study were: two high
solubility APIs (solubility > 1 mg/mL – valsartan and ibuprofen), two
intermediate solubility APIs (100 µg/mL < solubility < 1 mg/mL –
carvedilol and indomethacin), and two low solubility APIs (solubi-
lity < 100 µg/mL – tadalafil and bromocriptine mesylate) (Table 1).
The drugs were also selected to provide continuity to the inter-
laboratory dissolution studies performed with the μDISS Profiler™ [26].
2. Material and methods
2.1. Materials
Valsartan, ibuprofen, carvedilol, tadalafil, indomethacin and bro-
mocriptine mesylate (Table 1) were kindly provided through the Orbito
consortium with the exception of site number 6 who sourced ibuprofen
separately due to stock availability issues. FaSSIF powder was pur-
chased through Biorelevant.com. Sodium hydroxide (NaOH), mono-
basic sodium phosphate monohydrate (NaH2PO4·H2O) and sodium
chloride (NaCl) were purchased from Sigma Aldrich.
2.2. Methods
2.2.1. FaSSIF buffer and media preparation
FaSSIF and blank FaSSIF (both version1) were prepared using the
instructions supplied through Biorelevant.com [53], based on the
composition proposed by Galia et al. [54]. Blank FaSSIF was prepared in
the same way as FaSSIF with the exclusion of the FaSSIF powder.
2.2.2. Equipment
Sirius SDI equipment (Sirius Analytical, East Sussex,UK) was used
Background 
absorbance 
Surface 
absorbance 
IDR 
absorbance
Approx. location of 
top of sample cup 
Fig. 1. Image from the SDI analysis software while investigating valsartan dissolution in phosphate buffer. Picture from one partner taken from analysis software.
Within the software, the x-axis is the horizontal axis and the y-axis is the vertical axis, background absorbance zone (medium only) is the reference zone to account
for variations in media absorbance, the surface absorbance zone measures the concentration above the API compact surface, IDR absorbance zone measures the
concentration at the outlet which is used for IDR calculations by the software.
Table 1
Physicochemical properties of the 6 APIs investigated.
API Classification MW/FW pKa LogP LogD at pH6.5 Sapp FaSSIF/ Sapp blank FaSSIF Solubility (μg/mL)* Ref†
Bromocriptine mesylate Base 654.6/750.7 4.9 2.909 2.899 14.275 60.4 (Sapp FaSSIF)‡
3 (Sapp pH 6.5) ‡Δ
[26,44]
Carvedilol Base 406.5 7.9 2.784 1.384 2.738 136 (FaSSIF)
51.6 (Blank FaSSIF)
[45,46]
Ibuprofen Acid 206.3 4.4 2.904 0.804 1.146 1560 (FaSSIF)
7935 (pH 6.5)
[47–49]
Indomethacin Acid 357.8 4.5 4.30 2.3 435.8 (FaSSIF)
306.98 (Blank FaSSIF)
[50]
Tadalafil Base 389.4 0.85 (predicted) 2.61 2.61 0.997 2.5 (Sapp FaSSIF)‡
2 (pH not specified)
[26,51]
Valsartan Acid 435.5 4.7 3.942 2.142 951.609 (FaSSIF)
594–628 (Blank FaSSIF)
[26,52]
†Other sources for MW/FW and pKa were pubchem.ncbi.nlm.nih.gov and www.druginfosys.com, drugs@ FDA: FDA approved drug products.
ΔThe solubility value for bromocriptine mesylate was recorded after more than 400 min post exposure to the medium and there was evidence that the salt had
disproportionated to the parent.
‡ Sapp is the apparent solubility based on maximum concentrations from μDISS dissolution experiments.
* All solubility measurements were performed at 37 °C.
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for IDR assays. SDI data collection and analysis software (version
1.8.50814) was used to analyse the runs and values.
2.2.3. Solution preparation
Stock solutions of the APIs in FaSSIF and blank FaSSIF were pre-
pared. For higher solubility drugs (ibuprofen, valsartan, indomethacin
and carvedilol), a minimum five-point calibration curve (absorbance
(mAU) versus concentration (mM)) was created. Due to the low solu-
bility for some APIs, the mean molar extinction coefficient (MEC) of
three solutions of similar concentration was calculated. Up to 10% V/V
methanol was added to the solution as a co-solvent to increase solubi-
lity. Sonication was used where required to aid dissolution. In the ex-
periments, where methanol was added, and/or the solutions sonicated,
the medium used for blanking the system was treated in the same
manner.
2.2.4. Compact preparation
Approximately 4 mg of API was weighed into the micropress and for
compressed at 80 cN.m for 5 min using a calibrated torque wrench.
Compacts were prepared, where possible, just before measurement and
the compact’s surface area, assuming a flat surface, is 0.0314 cm2.
2.2.5. Molar extinction coefficient
The Molar Extinction Coefficient (MEC) was determined at each site
using the following methods at the same wavelength used for IDR work
The SDI pump and data collection software was programmed to run
for 10 min at 0.5 mL/min. The system was blanked with buffer and
when prompted a syringe containing the drug calibration solution
(4 mL) was loaded and pumped through the flow cell at 2 mL/min,
followed by resetting the pump to 0.5 mL/min. Each calibration con-
centration was run individually.
Two sites (sites 2 and 4) used the following alternative method. The
data collection software was setup to run continuously for 40 min. The
pump was operated manually (in withdraw mode) to flow standard
solutions through the dissolution cell at a flow rate of 1 mL/min for
4 min at each concentration. Blank medium was flushed through the
dissolution cell for 4 min before and after the standard solutions to
detect baseline drifts. The absorbance values were read and used for
construction of the calibration curve.
2.2.6. MEC data analysis
Where a calibration curve of absorbance versus concentration was
utilised, a regression line was drawn through the plot and assessed to
ensure linearity was maintained at all concentrations and the MEC was
calculated by dividing the slope of the line by the path-length. Where
solutions of similar concentration were used, the mean MEC of the three
solutions was calculated and used for IDR work. The five-point cali-
bration was the preferred method but the alternative method was used
if solubility was too low (tadalafil and bromocriptine). Each site de-
termined and used their own MECs and comparisons between sites was
carried out by calculating the mean MEC.
2.2.7. IDR
The SDI flow cell temperature was set to 37 °C and the appropriate
wavelength filter installed. If air bubbles in the flow cell were proble-
matic, the media could be pre-warmed to minimise the risk of air
bubble appearance. The pump settings on the data collections software
were adjusted as detailed in Table 2. The wavelengths and flow rates
were optimised at one site before the study. Optimisation was carried
out to maintain as high a concentration within IDR zone as possible
(whilst remaining in the linear range). The same flow rate could not be
used for all compounds due to the differences in solubility.
Partners were provided with defined methods to follow for IDR
determination. All sites were requested to follow the standardised
procedure for compact preparation, flow rate and wavelength condi-
tions, and for data analysis.
2.2.8. IDR determination
The system was previewed and blanked, then the sample was loaded
into the cell insert when prompted by the instrument. The system was
flushed with media three times at the elevated angle to remove air
bubbles, during the third flush the cartridge was lowered to the hor-
izontal position and data collection restarted. The above IDR steps were
repeated until six acceptable results were obtained. Results were
deemed unacceptable if one or more of the following exclusion criteria
were met: negative IDR values, air bubbles in the system, and where the
RSD values over 60 s intervals exceeded 10%. These features indicated
a possible failure of the run and/or compact formation.
2.2.9. IDR data analysis
The MEC, molecular weight and compact weight were entered into
the data analysis software. The z-origin was adjusted so that there was
no increase in absorbance after the first point, this was visualised in
concentration/absorption profile tab of the software.
The mean and standard deviation of each compact were calculated
from the data points collected 6 to 20 min after initiation of the dis-
solution experiment (21 to 40 min for tadalafil). Early work by one
partner investigated when the IDRs measurements should be taken, at
these points it is expected that the curves would be linear, and due to
continuous flow sink conditions are assumed. Once six replicates were
accepted, the mean and standard deviation were calculated using the
mean IDR from each run. If an IDR for one compact exceeded 1.64
standard deviations from the overall mean (90% of normally dis-
tributed results should fall within this range), then the result was ex-
cluded and repeated. Outliers could be excluded as they do not signify
normal IDR for the compounds. This could be due to issues with com-
pact formation or media blanking. A maximum of two runs could be
excluded in this way. For the final included data set the mean, standard
deviation, RSD, median and quartiles was calculated for comparison.
Between site comparisons were conducted on mean IDRs for each
site. From these data the overall mean IDRs, standard deviations and
RSDs were calculated.
3. Results and discussion
The variability associated with dissolution testing experiments
performed using the SDI systems has not previously been studied. Six
compounds were selected based on initial work by one partner.
One partner (site 6) had technical difficulties with their SDI system
and the team were not able to complete the experimental work in
house. In an effort to provide a full data set, the syringe pump, cartridge
and tools from the site’s system were transferred to another site and
used with a detector and heating block from another SDI system. A
crossover compound (indomethacin, with the blank FaSSIF medium)
was also examined. These experiments were analysed and have been
kept separate from the original site 6 data and have been designated as
site 7 in results. Indomethacin in blank FaSSIF was selected as all other
sites had data for this API/medium combination and there was suffi-
cient quantity of the API to allow a duplicate run including MEC to be
completed. It was originally intended that this data could be used to
Table 2
The wavelength, flow rate and run time for each of the six APIs under in-
vestigation.
API Wavelength (nm) Flow Rate (mL/
min)
Run Time
(min)
Bromocriptine Mesylate 254 0.1 20
Carvedilol 280 0.2 20
Ibuprofen 254 0.2 20
Indomethacin 254 0.5 20
Tadalafil 280 0.1 40
Valsartan 254 0.8 20
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provide a complete dataset for site 6, however this was not possible (see
IDR results).
3.1. MEC
Each site measured MECs to take into account possible differences
with respect to system performance, including lamp age. A single MEC
used for all sites was not appropriate as the UV lamps are not re-
placeable and the systems used were of varying ages, with differences in
the number of lamp hours. Additionally, the bandpass filters were dif-
ferent and differences in UV transmission between the filters is possible.
During analysis, path length was not altered, the equipment has a
standard path length of 0.4 cm.
The mean MECs were used to give an indication of the variability
between systems in terms of detector performance. The variability of
carvedilol in FaSSIF was the greatest at around 45% RSD (with a range
of 4900–16,000). The variability of carvedilol in blank FaSSIF was also
high at around 37% RSD, with the MEC at one site around half the value
of the highest (see Supplementary Material - Table 5). See Fig. 2 for the
MEC determined at each site. One reason for the higher variability in
tadalafil and carvedilol may be due to their relatively low solubility
compared to other compounds in this study that have a higher solubi-
lity.
Where the calibration curve method was used, absorbance vs con-
centration was shown to be linear across the concentration range. There
is no evidence that the different methods for MEC determination affect
the results since MEC values at sites which used method 2 shows no
pattern of high or low values. As the work was investigational it was
assumed that the stated concentrations were accurate and no ortho-
gonal determination of the solution concentrations was carried out.
3.2. IDR
IDR can provide useful information in early drug development,
especially small-scale methods where only a small quantity is required.
It can be used to provide information on the performance of different
API forms and salts to guide selection. The overall mean IDR for each
API in the different media can be found in Table 3. The highest solu-
bility APIs had the highest IDR values. The intermediate solubility drug
substances (carvedilol and indomethacin) had intermediate IDR values
while tadalafil and bromocriptine mesylate had the lowest values.
The equations for dissolution rate and IDR (Eqs. (1), (3) and (4))
assume that the concentration at the API surface is the same as the
solubility in the bulk medium. This is however variable depending on
the microenvironment surrounding the surface. As an ionisable com-
pound dissolves, the pH in the static layer in contact with the com-
pound can be increased or decreased from the bulk for bases and acids
respectively [55,56]. Where the pKa is close to the pH of the bulk
medium, there is the possibility that pH changes can affect the solubi-
lity within the boundary layer at the compact surface. While this is
difficult to overcome, awareness of the differences in solubility is im-
portant. For all APIs studied here, with the exception of tadalafil, there
is a risk that the surface solubility is lower than the bulk due to pH
changes thus decreasing the IDR. The compact surface pH was not
determined in this study and therefore the possible impact of this effect
has not been investigated. Each compound was investigated with a set
flow rate, changes to this flow rate may alter the microenvironment at
the compact surface and could be applied to study this phenomenon.
Buffer capacity and buffer type has also been shown to affect the
dissolution rate. Krieg et al. demonstrated for ibuprofen and in-
domethacin that changing the buffer capacity will result in an increase
in dissolution rate without a change in bulk pH [55]. It is not only the
buffer capacity which can affect dissolution since in the same study
Krieg et al. showed that bicarbonate and phosphate buffers with the
same capacity, show different IDRs [55]. The work conducted here was
carried out using a phosphate buffer with a set buffer capacity based on
the recipe provided Biorelevant, therefore the results here can be
compared between sites.
Site 6 utilised a different ibuprofen supply and to assess this internal
studies at site 1 (not published) investigated the difference in IDR
Fig. 2. MEC values determined in dissolution media by UV imaging at each site. Val – valsartan, Ibu – ibuprofen, Car – carvedilol, Ind – indomethacin, Tad – tadalafil,
Bro – bromocriptine mesylate, FaS – FaSSIF, Bl FaS – blank FaSSIF. Insert is close up of ibuprofen results for clarity. Error bars on mean marker represent 1 standard
deviation, where not visible, the error bars do not extend beyond the symbol. Mean MEC was calculated as a mean of individual sites as some were calculated from a
calibration curve.
K. Etherson, et al. European Journal of Pharmaceutics and Biopharmaceutics 150 (2020) 24–32
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between four ibuprofen sources. It was found that the IDR of the OrBiTo
supplied ibuprofen was statistically higher than commercial supplies
from Sigma-Aldrich and BASF. While this may have affected measured
IDR values, it was not sufficient to affect the overall rank order of the
compounds.
The variability of the IDR results observed here for all replicates
(33% to 130%) is similar to the μDISS IDR disc results from the inter-
laboratory study described earlier [26] where the coefficient of varia-
tion observed ranged from around 55% to 110%. These variabilities
show that the SDI has a similar robustness to the μDISS. Robust intersite
performance is important, if during the development of a compound it
may be analysed using different systems. It is beneficial to have an
understanding on potential differences between different systems in
use, giving confidence to the results achieved.
From Table 3, the IDR for indomethacin in blank FaSSIF is similar
between sites 6 and 7, however, valsartan had a lower IDR than ex-
pected in blank FaSSIF. It was not clear why this was the case. As a
result site 7 was treated independently to site 6.
Due to the unavailability of the raw data; the indomethacin IDR
values were recalculated post-analysis at site 7 using the correct MEC
value according to Beer-Lambert Law.
3.2.1. Results in rank order of mean IDR
Data across the sites has been tabulated in overall rank order of
mean IDR for both FaSSIF and blank FaSSIF. In FaSSIF media, the
overall rank order of mean IDR was ibuprofen > valsartan >
indomethacin > carvedilol > bromocriptine mesylate > tadalafil.
This rank order follows the rank order of solubility. Only sites which
Table 3
Overall mean IDR values for each drug in both media. Individual site means
also detailed.
Drug Media Overall
Mean (μg/
min/
cm2)a
(SD)
[RSD]
Site Site Mean
(μg/min/
cm2) (SD)
RSD n† Total
runs ‡§
Bromocriptine
Mesylate
FaSSIF 3.4
(2.7)
[82%]
Site 1 2.0
(0.90)
45% 6 8
Site 2 1.7
(0.40)
24% 6 7
Site 3 3.1
(0.74)
24% 6 7
Site 4 4.0 (2.4) 60% 6 8
Site 5 0.43
(0.18)
42% 6 15
Site 6 8.2 (4.4) 54% 4 7
Blank
FaSSIF
2.2
(2.7)
[20%]
Site 3 6.4 (6.1) 96% 6 6
Site 4 2.1 (2.0) 94% 6 9
Site 6 4.4 (4.7) 110% 6 8
Carvedilol FaSSIF 7.1
(4.2)
[59%]
Site 1 3.7
(0.78)
21% 6 6
Site 2 10 (1.5) 14% 6 8
Site 3 4.3 (1.3) 30% 6 7
Site 4 5.9 (2.3) 39% 6 13
Site 7 11 (5.8) 51% 6 6
Blank
FaSSIF
3.6
(2.3)
[65%]
Site 1 4.0 (1.8) 45% 6 6
Site 2 3.6
(0.41)
11% 6 8
Site 3 2.0
(0.51)
25% 6 12
Site 4 6.4 (2.9) 46% 6 12
Site 7 1.4
(0.88)
62% 5 6
Ibuprofen FaSSIF 75
(24)
[33%]
Site 1 66 (13) 20% 6 8
Site 2 89 (17) 19% 6 8
Site 3 89 (16) 18% 6 10
Site 4 60 (8.4) 14% 6 7
Site 5 47 (8.3) 18% 6 7
Site 6 110 (22) 20% 4 7
Blank
FaSSIF
66
(30)
[46%]
Site 1 55 (15) 27% 6 6
Site 2 57 (16) 28% 6 12
Site 3 57 (13) 22% 6 8
Site 4 73 (7.1) 9.7% 6 7
Site 5 50 (17) 34% 6 8
Site 6 120 (52) 42% 4 6
Indomethacin FaSSIF 19
(15)
[79%]
Site 1 8.9
(0.90)
10% 6 7
Site 2 22 (4.1) 19% 6 6
Site 3 19 (5.9) 32% 6 8
Site 4 15 (2.2) 15% 6 10
Site 5 7.9 (1.5) 19% 6 6
Site 6 47 (22) 46% 5 6
Blank
FaSSIF
13
(4.8)
[38%]
Site 1 8.4
(0.86)
10% 6 8
Site 2 16 (2.3) 15% 6 9
Site 3 16 (7.5) 47% 6 10
Site 4 15 (2.5) 16% 6 10
Site 5 8.8 (1.3) 15% 6 7
Site 6 13 (5.6) 44% 2 6
Site 7 12 (7.4) 63% 2 3
Table 3 (continued)
Drug Media Overall
Mean (μg/
min/
cm2)a
(SD)
[RSD]
Site Site Mean
(μg/min/
cm2) (SD)
RSD n† Total
runs ‡§
Tadalafil FaSSIF 2.1
(2.7)
[130%]
Site 1 0.80
(0.38)
47% 6 6
Site 2 0.33
(0.049)
15% 6 9
Site 3 1.5
(0.60)
39% 6 6
Site 4 6.6 (3.8) 59% 6 7
Site 5 1.5
(0.50)
34% 6 8
Site 6 2.1 (2.3) 110% 5 7
Blank
FaSSIF
2.9
(3.3)
[120%]
Site 3 0.62
(0.28)
45% 6 8
Site 4 7.4
(0.59)
7.9% 6 7
Site 6 0.59
(0.28)
47% 6 8
Valsartan FaSSIF 48
(21)
[43%]
Site 1 25 (3.8) 16% 6 6
Site 2 60 (8.9) 15% 6 9
Site 3 75 (11) 15% 6 6
Site 4 50 (15) 30% 6 7
Site 5 45 (7.0) 16% 6 11
Site 7 20 (12) 59% 3 4
Blank
FaSSIF
37
(16)
[45%]
Site 1 34 (5.6) 16% 6 7
Site 2 51 (3.1) 6.0% 6 9
Site 3 18 (6.6) 37% 6 10
Site 4 52 (5.6) 11% 6 6
Site 5 44 (7.4) 17% 6 6
Site 6 37 (3.8) 10% 2 3
Site 7 4.2 (1.8) 42% 3 6
§Site 4 used some compounds for training purposes (increasing the number of
runs).
‡Number of runs per site.
a Overall mean calculated from all replicates from all sites.
† Number of replicates per site.
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were able to complete all six compounds were included in this analysis.
The rank order was not maintained at site 4 compared to the overall
sites 1–3 rank order, with tadalafil, carvedilol, and bromocriptine me-
sylate having a different order (Fig. 3).
At site 5, the rank order was ibuprofen > valsartan >
indomethacin > tadalafil > bromocriptine mesylate. At site 6, the
rank order was ibuprofen > indomethacin > bromocriptine mesy-
late > tadalafil. At site 7 only two compounds were tested in FaSSIF,
the rank order was as expected for these compounds based on the
grouped rank order.
Differences between site rank order are not wholly unexpected in
biorelevant media as variations can be observed in the micelles [15].
The work with blank FaSSIF was not planned to be carried out on
tadalafil and bromocriptine mesylate due to their low solubility and
they are therefore excluded from this analysis. The rank order was
ibuprofen > valsartan > indomethacin > carvedilol (Fig. 4) with
the rank order maintained between the 4 sites which completed the
four compounds. As above the rank order followed the rank order for
solubility.
The rank order of the high and intermediate compounds at sites 5
and 6 followed the same rank order. At site 7, however, valsartan had a
lower IDR than expected and it was not clear why this was the case.
If we look at all six compounds it was observed that overall, bro-
mocriptine mesylate showed greater IDR values than carvedilol. A
number of factors affect dissolution rate, and lower solubility com-
pounds having a faster rate of dissolution is not unexpected, which may
be affecting the dissolution rate in the blank FaSSIF medium.
Although the overall rank orders observed for FaSSIF was the same
as solubility, it should not be assumed that solubility rank order directly
translates into IDR rank order. This was the case for bromocriptine and
carvedilol, in blank FaSSIF.
3.3. SDI versus μDISS
Five of the APIs studied here were also studied in the μDISS
Profiler™ system, carvedilol was not included in the study by Andersson
et al. and is not included in this part of the discussion [26]. The study by
Andersson et al. determined IDR on both API powder and compacted
discs, only the disc IDRs will be discussed and the mean IDR compar-
isons can be found in Fig. 5. Direct comparisons between the IDR values
were not appropriate as the conditions were different between the
methods. The rank order for the disc IDRs in FaSSIF for μDISS Profiler™
was valsartan > ibuprofen > indomethacin > bromocriptine me-
sylate > tadalafil [26]. This differs from the rank order for the current
SDI work: ibuprofen > valsartan > indomethacin > bromocriptine
mesylate > tadalafil. The high solubility compounds have switched
places but apart from that the order is identical. When the μDISS IDR is
plotted against the SDI values a linear relationship was not observed,
with an R2 value of 0.55. Valsartan appears to be an outlier in the data.
When valsartan is excluded a linear relationship with an R2 value of
0.98 is observed. It is unclear whether valsartan IDR is over or under
estimated in the μDISS or SDI respectively. One possibility for the re-
sults is due to valsartan being a high solubility, high UV absorbance
compound, which could be affecting the IDR results measured in both
studies. Further work is needed on high solubility, high absorbance
compounds to allow that distinction to be made. Another possibility
could be the differences in the compact microenvironments between
the static and flow through systems. APIs will dissolve to saturation
around the compact before diffusing into the bulk media, as the hy-
drodynamics of both static and flow through systems differ there could
be an effect on IDR. The IDR values for the SDI and μDISS are expected
to differ based on the differences between the systems. The SDI utilises
a static compact where medium is passed over the compact at a set flow
rate whereas the μDISS utilises a rotating compact. The method of de-
tection varies between the two systems also. Where the SDI detects a
single wavelength the μDISS detects across the spectrum and a range
can be used. The quantitative performance of the UV imaging setup
(SDI) with respect to determining dissolution rates has previously been
assessed [57,58]. As with solubility, IDRs measured are affected by
different measurement conditions and comparisons between different
techniques should be qualitative. A comparison to Wood’s apparatus is
recommended, ideally using the same batch of APIs used in this study,
as well as running carvedilol using the same μDISS methods used by
Andersson et al. [26].
Fig. 3. Rank order IDR of compounds in FaSSIF. Only sites which completed all
6 compounds in FaSSIF are included. ( ) Site 1, ( ) Site 2, ( ) Site 3, ( ) Site
4, ( ) group rank order. Ibu – ibuprofen, Val – valsartan, Ind – indomethacin,
Car – carvedilol, Bro – bromocriptine mesylate, Tad – tadalafil.
Fig. 4. Rank order IDR of compounds in FaSSIF. Only sites which completed all
moderate and high solubility compounds in FaSSIF are included. ( ) Site 1, ( )
Site 2, ( ) Site 3, ( ) Site 4, ( ) group rank order. Ibu – ibuprofen, Val –
valsartan, Ind – indomethacin, Car – carvedilol.
Fig. 5. IDR comparison between SDI ring study and μDISS ring study. All results
in FaSSIF at 37 °C. ( ) Bromocriptine Mesylate, ( ) Ibuprofen, ( )
Indomethacin, ( ) Tadalafil, ( ) Valsartan.
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3.4. Single operator analysis
To investigate the variability introduced by different operators
carrying out the analysis at multiple sites it was decided that one person
would process the indomethacin data for all sites in both FaSSIF and
blank FaSSIF media. Variability due to operator can occur due to in-
consistencies in FaSSIF preparation as it is known that micelle size is
particularly sensitive to the concentration of SIF used [15]. Further
source of variability between operators can occur with the placement of
the z-origin in the analysis software. This origin determines the amount
of absorption data included in IDR determinations. Operators were in-
structed on setting the origins within the software as part of the shared
methods.
Raw data files from sites 1 to 6 were sent to a single operator for
analysis, along with details of the indomethacin MEC in both FaSSIF
and blank FaSSIF. Site 7 was excluded from the analysis as raw SDI files
were not available. In FaSSIF medium, the single operator analysis
improved the variability (Table 4) over all sites. When blank FaSSIF
medium was used, single operator analysis did not reduce the observed
variability.
While single operator analysis successfully reduced the variability of
the mean IDR in FaSSIF, there was a lack of improvement in the lower
variability blank FaSSIF analysis. The larger variability difference for
FaSSIF could be narrowed down to site 6. If this site is excluded from
the analysis then the site analysis mean reduced to 14 μg/min/cm2 with
an RSD of 44%, which is similar to the single operator analysis. A
reason for this deviation at one site was not determined but could be
down to operator error. From this analysis it shows that following a
standard protocol for IDR determination, which includes data analysis
methods, reduces the variability from different interpretations for
origin placement. Following a set protocol for both conducting the
experiments and analysing the results will improve the intrasite com-
parisons between individuals using the same piece of equipment as-
suming the same medium is used.
Only one compound was chosen for single operator analysis to
highlight the possible differences in user analysis. Although partners
were provided guidance on analysis there may have been instances
where this was deviated from. The object of the work here was to in-
vestigate the variability between sites, as a single user would not be
present at each site in a real-world scenario the sites would only have
internal data for comparisons. This analysis highlights the importance
of defining the method of analysis to be used at a site to allow com-
parison between different compounds. It is suggested that all users at
each site should be trained on the analysis protocol.
4. Conclusions
Disc IDRs were measured for all six compounds at most partici-
pating sites with reasons for not achieving universal coverage due to
technical issues and lack of available API. The study has shown that, in
general, rank order for overall mean IDR was similar to solubility rank
order in both FaSSIF and blank FaSSIF. Variability between sites ranged
between 33% and 130%, and was highest for lower solubility com-
pounds. This level of variability was similar to the variability observed
between another interlaboratory small-scale IDR study [26].
The variability for a selected compound was investigated by a single
operator. With the exception of one site, IDRs were similar for both
media following single operator analysis. Therefore, having and fol-
lowing a standard method, for data collection and analysis will help to
reduce variability during intra and inter laboratory experiments.
The observed variability is likely related to an intrinsic variability
which can be expected between systems and is difficult to reduce fur-
ther with experimental controls. While the rank order for the three
lowest solubility compounds was not maintained, the high and low
solubility compounds were successfully separated according to IDR at
the sites. It is important that the MEC values are measured using the
system on which the IDR will be determined.
The data here shows that the SDI can be used in early development
work to measure IDR. The variability is similar to the μDISS Profiler™.
The advantage this system has over others is the imaging capabilities.
For APIs at risk of, for example, gelling or form changes, this can be
observed from the videos produced. Powder release from the compact
surface or compact disintegration can be detected and visualised using
the imaging, providing information on the behaviour of the API. For the
majority of compounds, the two different small-scale IDR methods
compared here are likely to be suitable. An internal database of
knowledge should be gathered for allowing comparisons between APIs
to make determinations. Further work is required to investigate the
suitability of the SDI method for high solubility, high absorbance drugs.
The current study highlights the challenges associated with de-
termining a seemingly simple but important parameter affecting the
performance of drug candidates. Variability at and between sites is
remarkable and should be kept in mind assessing dissolution rate data.
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